You are here: Industry Insights > Market News > Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Jackfruit Powder

Pineapple Powder

Musang King Durian Powder

Noni Enzyme Powder

VITAMIN B12

hydraulic column packer/protein chromatography column/prepacked gel column packer

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

firstwordpharmaJuly 12, 2021

Tag: Sputnik V , COVID-19 , mRNA vaccine , SARS-CoV-2

Favorites

Viral vector and mRNA vaccines, including Russia's Sputnik V, provide enough protection against the new Delta strain of the coronavirus, albeit to a lesser extent, reported The Times of India.

The observation was made by Sergey Netesov, head of the Novosibirsk State University's Laboratory and member of the Russian Academy of Sciences.

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

They offered 95% protection against the initial strain and now they give 90% protection against the Delta variant, Netesov said.

Sputnik V uses two different engineered adenoviruses (rAd26 and rAd5 for the first and second doses, respectively) to deliver the genetic code for the spike protein of SARS-CoV-2.

Previous:Unvaccinated Belgian woman contracted two COVID variants simultaneously

Next:Israeli co Bonus BioGroup reports Covid-19 treatment success

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

InnoCare Pharma announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment patients with non-segmental vitiligo in China.

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist | Pharmasources.com

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

PR NewswireMay 14, 2025

iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, announced the first use of the iotaSOFT? Insertion System outside of the United States.

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

Related News

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

You may like
More>>

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Sputnik V gives 90% protection against Delta strain of Covid-19: Scientist

Related News

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

You may likeMore>>

You may like
More>>